A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-4250 Monotherapy in Anti-Retroviral Therapy (ART)-Naive, HIV-1 Infected Subjects
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2018
At a glance
- Drugs MK-4250 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 24 Jan 2018 Status changed from not yet recruiting to recruiting.
- 10 Jan 2018 Planned initiation date changed from 8 Jan 2018 to 12 Jan 2018.
- 03 Jan 2018 Planned initiation date changed from 27 Dec 2017 to 8 Jan 2018.